Bilateral Carpal Tunnel Syndrome Induced by Nivolumab Immunotherapy

Checkpoint inhibitors have been the cornerstone in the treatment of many advanced cancers. Despite their efficacy, these therapies can lead to a wide range of immune-related adverse events, some of which may cause neurological toxicity and present significant clinical challenges. We describe the case of a 78-year-old man who developed bilateral carpal tunnel syndrome while receiving nivolumab for metastatic collecting duct carcinoma of the kidney. His symptoms showed marked improvement following corticosteroid therapy and the discontinuation of immunotherapy. This case underscores the critical need for the prompt recognition and collaborative management of neurological immune-related adverse events to optimize patients' outcomes.